1887

Abstract

Purpose. Escherichia coli is a leading cause of bloodstream infection (BSI) in hospitals and communities.

Methodology. We conducted a retrospective study in 2015 to evaluate the clinical features and microbiological characteristics of E. coli BSI acquired in the hospital and community.

Results. A total of 100 patients with E. coli BSI were enrolled, among whom 60 % had hospital-onset (HO) BSI while 40 % had community-onset (CO) BSI. Patients with HO BSI had higher percentages of haematological disorders, immunosuppression conditions, underwent surgery within 2 weeks and had a higher 30-day mortality. The prevalences of multidrug-resistant and extended-spectrum β-lactamase-producing strains were 81 and 60 %, respectively. Resistance percentages to ampicillin, ampicillin-sulbactam, cefazolin, ceftriaxone, ciprofloxacin and levofloxacin were greater than 50 %. Of the 43 different sequence types (STs) identified, ST131 (15.3 %) was the most common. The serum agglutination rate was 52 % in which 13 O and 11 H serogroups were observed. Among the 36 detected virulence factor (VF) genes, IutA (66 %) and traT (61 %) were the most predominant. papA, papC and papEF were different between the CO and HO BSI groups. VF scores were high (mean >7) in the frequently detected ST95, ST1193 and ST131.

Conclusion. This study revealed that the clinical features of HO and CO E. coli BSI were different. STs and serotypes showed a great diversity in this region while VF genes of the isolates varied between clones.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000904
2019-01-09
2019-10-16
Loading full text...

Full text loading...

References

  1. Laupland KB, Church DL. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 2014;27:647–664 [CrossRef][PubMed]
    [Google Scholar]
  2. Bhattacharya A, Nsonwu O, Johnson AP, Hope R. Estimating the incidence and 30-day all-cause mortality rate of Escherichia coli bacteraemia in England by 2020/21. J Hosp Infect 2018;98:228–231 [CrossRef][PubMed]
    [Google Scholar]
  3. Musicha P, Cornick JE, Bar-Zeev N, French N, Masesa C et al. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study. Lancet Infect Dis 2017;17:1042–1052 [CrossRef][PubMed]
    [Google Scholar]
  4. Poolman JT, Wacker M. Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J Infect Dis 2016;213:6–13 [CrossRef][PubMed]
    [Google Scholar]
  5. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998;95:3140–3145 [CrossRef][PubMed]
    [Google Scholar]
  6. Mathers AJ, Peirano G, Pitout JD. Escherichia coli ST131: The quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 2015;90:109–154 [CrossRef][PubMed]
    [Google Scholar]
  7. Santos ACM, Zidko ACM, Pignatari AC, Silva RM. Assessing the diversity of the virulence potential of Escherichia coli isolated from bacteremia in São Paulo, Brazil. Braz J Med Bio Res 2013;46:968–97310 [CrossRef]
    [Google Scholar]
  8. Skjøt-Rasmussen L, Ejrnæs K, Lundgren B, Hammerum AM, Frimodt-Møller N. Virulence factors and phylogenetic grouping of Escherichia coli isolates from patients with bacteraemia of urinary tract origin relate to sex and hospital- vs. community-acquired origin. Int J Med Microbiol 2012;302:129–134 [CrossRef][PubMed]
    [Google Scholar]
  9. Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, Golan Y, Noy A et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 2002;34:1431–1439 [CrossRef][PubMed]
    [Google Scholar]
  10. Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009;31:146–150 [CrossRef][PubMed]
    [Google Scholar]
  11. Michalopoulos A, Falagas ME, Karatza DC, Alexandropoulou P, Papadakis E et al. Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients. Am J Infect Control 2011;39:396–400 [CrossRef][PubMed]
    [Google Scholar]
  12. CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement, CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2014
    [Google Scholar]
  13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–281 [CrossRef][PubMed]
    [Google Scholar]
  14. Ejrnæs K, Stegger M, Reisner A, Ferry S, Monsen T et al. Characteristics of Escherichia coli causing persistence or relapse of urinary tract infections: phylogenetic groups, virulence factors and biofilm formation. Virulence 2011;2:528–537 [CrossRef][PubMed]
    [Google Scholar]
  15. Koga VL, Tomazetto G, Cyoia PS, Neves MS, Vidotto MC et al. Molecular screening of virulence genes in extraintestinal pathogenic Escherichia coli isolated from human blood culture in Brazil. Biomed Res Int 2014;2014:1–9 [CrossRef]
    [Google Scholar]
  16. Matsumura Y. Multilocus sequence typing (MLST) analysis. Rinsho Byori 2013;61:1116–1122[PubMed]
    [Google Scholar]
  17. Williamson DA, Lim A, Wiles S, Roberts SA, Freeman JT. Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005-2011. BMC Infect Dis 2013;13:385 [CrossRef][PubMed]
    [Google Scholar]
  18. Bou-Antoun S, Davies J, Guy R, Johnson AP, Sheridan EA et al. Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014. Euro Surveill 2016;21: [CrossRef][PubMed]
    [Google Scholar]
  19. van der Mee-Marquet NL, Blanc DS, Gbaguidi-Haore H, dos Santos Borges S, Viboud Q et al. Marked increase in incidence for bloodstream infections due to Escherichia coli, a side effect of previous antibiotic therapy in the elderly. Front Microbiol 2015;6:646 [CrossRef][PubMed]
    [Google Scholar]
  20. Rojas L, Muñoz P, Kestler M, Arroyo D, Guembe M et al. Bloodstream infections in patients with kidney disease: risk factors for poor outcome and mortality. J Hosp Infect 2013;85:196–205 [CrossRef][PubMed]
    [Google Scholar]
  21. Quan J, Zhao D, Liu L, Chen Y, Zhou J et al. High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China. J Antimicrob Chemother 2017;72:273–280 [CrossRef][PubMed]
    [Google Scholar]
  22. Vihta KD, Stoesser N, Llewelyn MJ, Quan TP, Davies T et al. Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998-2016: a study of electronic health records. Lancet Infect Dis 2018;18:1138–1149 [CrossRef][PubMed]
    [Google Scholar]
  23. Abernethy J, Guy R, Sheridan EA, Hopkins S, Kiernan M et al. Epidemiology of Escherichia coli bacteraemia in England: results of an enhanced sentinel surveillance programme. J Hosp Infect 2017;95:365–375 [CrossRef][PubMed]
    [Google Scholar]
  24. Cho SY, Kang CI, Cha MK, Wi YM, Ha YE et al. Clinical features and treatment outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli sequence type 131. Microb Drug Resist 2015;21:463–469 [CrossRef][PubMed]
    [Google Scholar]
  25. Wang S, Zhao SY, Xiao SZ, Gu FF, Liu QZ et al. Antimicrobial resistance and molecular epidemiology of Escherichia coli causing bloodstream infections in three hospitals in Shanghai, China. PLoS One 2016;11:e0147740 [CrossRef][PubMed]
    [Google Scholar]
  26. Namikawa H, Yamada K, Fujimoto H, Oinuma KI, Tochino Y et al. Clinical characteristics of bacteremia caused by extended-spectrum Beta-lactamase-producing Escherichia coli at a tertiary hospital. Intern Med 2017;56:1807–1815 [CrossRef][PubMed]
    [Google Scholar]
  27. Denis B, Lafaurie M, Donay JL, Fontaine JP, Oksenhendler E et al. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. Int J Infect Dis 2015;39:1–6 [CrossRef][PubMed]
    [Google Scholar]
  28. Zhao WH, Hu ZQ. Epidemiology and genetics of CTX-M extended-spectrum β-lactamases in Gram-negative bacteria. Crit Rev Microbiol 2013;39:79–101 [CrossRef][PubMed]
    [Google Scholar]
  29. Xia S, Fan X, Huang Z, Xia L, Xiao M et al. Dominance of CTX-M-type extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS One 2014;9:e100707 [CrossRef][PubMed]
    [Google Scholar]
  30. Zhang J, Zheng B, Zhao L, Wei Z, Ji J et al. Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals. BMC Infect Dis 2014;14:659 [CrossRef][PubMed]
    [Google Scholar]
  31. Edelsberg J, Weycker D, Barron R, Li X, Wu H et al. Prevalence of antibiotic resistance in US hospitals. Diagn Microbiol Infect Dis 2014;78:255–262 [CrossRef][PubMed]
    [Google Scholar]
  32. de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N et al. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 2013;19:860–868 [CrossRef][PubMed]
    [Google Scholar]
  33. Azargun R, Sadeghi MR, Soroush Barhaghi MH, Samadi Kafil H, Yeganeh F et al. The prevalence of plasmid-mediated quinolone resistance and ESBL-production in Enterobacteriaceae isolated from urinary tract infections. Infect Drug Resist 2018;11:1007–1014 [CrossRef][PubMed]
    [Google Scholar]
  34. Wang Z, Zhang H, Han J, Xing H, Wu MC et al. Deadly sins of antibiotic abuse in China. Infect Control Hosp Epidemiol 2017;38:758–759 [CrossRef][PubMed]
    [Google Scholar]
  35. Cha MK, Kang CI, Kim SH, Cho SY, Ha YE et al. Comparison of the microbiological characteristics and virulence factors of ST131 and non-ST131 clones among extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia. Diagn Microbiol Infect Dis 2016;84:102–104 [CrossRef][PubMed]
    [Google Scholar]
  36. Riley LW. Pandemic lineages of extraintestinal pathogenic Escherichia coli. Clin Microbiol Infect 2014;20:380–390 [CrossRef][PubMed]
    [Google Scholar]
  37. Razaghi M, Tajeddin E, Ganji L, Alebouyeh M, Alizadeh AHM et al. Colonization, resistance to bile, and virulence properties of Escherichia coli strains: unusual characteristics associated with biliary tract diseases. Microb Pathog 2017;111:262–268 [CrossRef][PubMed]
    [Google Scholar]
  38. Szemiako K, Krawczyk B, Samet A, Śledzińska A, Nowicki B et al. A subset of two adherence systems, acute pro-inflammatory pap genes and invasion coding dra, fim, or sfa, increases the risk of Escherichia coli translocation to the bloodstream. Eur J Clin Microbiol Infect Dis 2013;32:1579–1582 [CrossRef][PubMed]
    [Google Scholar]
  39. Micenková L, Beňová A, Frankovičová L, Bosák J, Vrba M et al. Human Escherichia coli isolates from hemocultures: Septicemia linked to urogenital tract infections is caused by isolates harboring more virulence genes than bacteraemia linked to other conditions. Int J Med Microbiol 2017;307:182–189 [CrossRef][PubMed]
    [Google Scholar]
  40. Mendis SM, Vasoo S, Johnston BD, Porter SB, Cunningham SA et al. Clinical and molecular correlates of Escherichia coli bloodstream infection from two geographically diverse centers in Rochester, Minnesota, and Singapore. Antimicrob Agents Chemother 2018;62: [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000904
Loading
/content/journal/jmm/10.1099/jmm.0.000904
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error